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Abstract  
The present study was carried out in Genetic Engineering and biotechnology Institute –Baghdad University 
during a period from October 2013 to October 2014, for detecting the role of genetic alterations of FGFR3 gene 
in Iraqi patients with bladder cancer. 50 patients with bladder cancer who admitted to Ghazi AlHariri Hospital in 
Baghdad and 25 healthy persons (age between 30 to 86 years) were included in this study.   Total genomic DNA 
was isolated from blood samples for molecular analysis using specific primers for exon 7 of the gene FGFR3. 
The PCR amplified regions of the FGFR3 exon 7 of healthy and patients showed a molecular weight of about 
120 bp. The analysis of mutation using restriction fragment length polymorphism (RFLP) was performed on 
PCR products of FGFR3 exon 7 using Hae II and TseI enzymes. These results showed that the PCR amplified 
regions of the FGFR3 exon 7 has only one restriction site for each enzymes. The REFLP molecular analysis of 
FGFR3 exon 7 of patient samples for both enzymes revealed one mutation in one patient include FGFR3 
Arginine 248 Cysteine  mutation. The DNA sequencing analysis of the exon 7 PCR products revealed that 
among 50 patients included in this study, 51 mutations were detected in exon 7. The mutations detected in exon 
7 include three types, g.13515 del C , g.13510 del A and g.13529 ins A. The more frequent mutation was 
g.13515 del C which detected in 34 patients followed by g.13510 del A and g.13529 ins A mutations which 
detected in 12 and 1 patients respectively. The A insertion mutation (13529) were included in the Hae II 
restriction site which explain the single mutation detected in patients. The results showed that the exon 7,  g.1315 
delC mutation is a correlated with the initiation of tumor since it detected in all grads and consist of the majority 
of detected mutations (36/81, 44.4%). On the other hand, exons 7 mutations, g.13529 ins A, g.13510 del A, 
showed to have importance in cancer initiation and development since they are detected in the early grade (G1) 
and in 38(80.9%) patients of 47. 
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Introduction: 
Bladder cancer is the ninth most common cancer diagnosis worldwide, with more than 330,000 new cases each 
year and more than 130,000 deaths per year, with an estimated male:female ratio of 3.8:1.0 (Ploeg, 2009). 
Approximately 90% of malignant tumors arising in the uroepithelium of the bladder are transitional cell 
carcinomas (TCC). It starts in the inner layer of the bladder (Siegel, 2012).  
This group has subtypes: Papillary cancers grow like tiny fingers from the inner bladder lining toward 
its hollow center, Flat cancers do not grow toward the center, These tumors are also named based on whether 
they have grown into the bladder wall, Non-invasive cancers are still in the inner layer of cells (the urothelium) 
but have not grown into the deeper layers (Lopez 2004), and Invasive cancers have grown into the deeper layers 
of the bladder. These cancers are more likely to spread and are harder to treat (Arianayagam, 2011).  
Other histologists include squamous cell carcinoma (1.5%), This type is much less common and is 
usually invasive. adenocarcinoma (1.2%), This type is also much less common, almost all are invasive, respond 
poorly to radiation with chemotherapy, and small cell carcinoma  (<1%), A very small number of bladder 
cancers are of this type. These cancers often grow quickly (Zhang  et al., 2012). Sarcomas start in the muscle 
cells of the bladder, but they are rare (Bodoor et al 2010), to find out more about sarcomas (Arianayagam and 
Rashid, 2011). Most superficial bladder tumors show a loss of heterozygosity (LOH) of chromosome 9 (Wada  et 
al.,2003). deletions on chromosome 9 are the most common chromosomal abnormalities in transitional cell 
carcinoma (TCC), which represents more than 50% of all grades and stages (Miyao et al., 1993). low-grade 
papillary tumors and LOH of chromosome 9 exhibit a constitutive activation of the receptor tyrosine kinase-Ras 
pathway, with activating mutations in the HRAS and fibroblast growth factor receptor 3 (Mitra et al., 2006). 
FGFR3 mutations are confined to hot spots in exons 7, 10, and 15, and all are predicted to cause constitutive 
activation of the kinase activity of the receptor, which in turn can activate the mitogen-activated protein kinase 
(MAPK) pathway—a pathway shared with the Ras family of proteins (Mitra et al., 2006). Mutations in FGFR3 
and the Ras genes (including HRAS), both mutations were found to be absolutely mutually exclusive, suggesting 
possible biological equivalence (Jebar et al., 2005). 
Approximately 80% of transitional cell carcinomas are confined to the epithelium (pTa, Carcinoma in 
situ) or lamina propria (pT1) at initial diagnosis, but the remaining 20% invade the muscularis propria (pT2, pT3, 
pT4). pTa lesions (papillary tumors) are the most common form of bladder carcinoma (Billerey et al., 2001).  
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More than 50% of primary bladder urothelial cell carcinomas, especially in low-grade and low-stage papillary 
tumors (Hernandez et al., 2005).  
Approximately 80% of transitional cell carcinomas are confined to the epithelium (pTa, Carcinoma in 
situ) or lamina propria (pT1) at initial diagnosis, but the remaining 20% invade the muscularis propria (pT2, pT3, 
pT4). pTa lesions (papillary tumors) are the most common form of bladder carcinoma (Billerey et al., 2001).  
More than 50% of primary bladder urothelial cell carcinomas, especially in low-grade and low-stage papillary 
tumors (Hernandez et al., 2005). Losses on chromosome 9 are apparently typical features of noninvasive low 
malignant papillary tumors. In pTa tumors, loss of chromosome 9 is similarly distributed in tumors with and 
without mutations (Bas et al.,2001).  Somatic activating mutions of FGFR3 occur with high frequency of 70% of 
cases in pTa tumors (superficial cases) but are absent or very rare in carcinoma in situ (Karoui et al., 2001). 
Same mutations are present in only 15% of muscle invasive bladdertumors.FGFR3 mutations are, therefore, 
considered to be a molecular marker of the pTa pathway.pT1 bladder tumors penetrate the basement membrane 
(Zieger  et al., 2005).   
According to the most recent (Iraqi cancer registry, 2010), bladder carcinoma is currently ranks sixth 
among the commonest ten cancers. The male gender seems to bear this problem than females in that it is the 
second most frequent cancer in males (827 cases) and Ninth position in females (274 cases) (Iraqi cancer registry, 
2010). 
This research aims for the detection of three novel mutations in exon 7 of FGFR3 gene in Iraqi patients 
with bladder cancer. 
 
Materials and Methods 
The study consisted of 50 subjects with bladder cancer (Transitional cells carcinoma TCC) and 25 subjects 
control group. Patient samples were obtained from Ghazi Al Hariri Hospital in Baghdad.  Patients age ranged 
from 30 to 86 years while control subjects ages ranged from 30 to 50 years. Blood samples (3-5ml) were 
collected from patients and control in EDTA anticoagulant tubes. Questionnaire form was filled for each 
patient including; name, age, gender, employment type and smoking.   
DNA extraction  
Total genomic DNA was isolated from the blood, for molecular studies using genomic DNA purification kits 
(Bioneer ) South Korea. 
Polymerase chain reaction (PCR) for exon 7(120bp)         
The exon 7 region of FGFR3 was amplified by PCR using the primers, F 5' CGGCAGTGGCGGTGGTGGTG'3 
and R 5'  AGCACCGCCGTCTGGTTG '3 and the condition, initial denaturation 5 minutes at 95 
o
C, followed by 
40 cycle each of denaturation 1 minute at 95 
o
C, annealing 1 minute at 67 
o
C, extension 1 minute at 72 
o
C and a 
final extension step at 72 
o
C for 10 minute.  PCR products (3 µl) were then separated on 3% agarose gel with a 
ladder (100bp) and visualized.  
Screening for mutations in exon 7 using RFLP analysis 
Screening of the FGFR3  mutations in exon 7 was performed by digestion with restriction endonuclease HaeII 
(New England Biolab Beverly, MA, USA) and TseI (New England Biolab). The PCR product (10 µL) was 
digested with 1 U of each restriction enzyme in 20 µL for 1 h at 37°C for HaeII and at 65°C for TseI. Each 
product was analyzed by 3% agarose gel then photographed under ultraviolet light. 
PCR products Sequencing 
The PCR products of the FGFR3 gene exon 7 region (50 samples)   and primers were sent by Macrogen 
Company (U.S.A) for sequencing. The sequences of these samples were compared with the information in gene 
bank of the National Center for Biotechnology Information (NCBI) for standard FGFR3 gene, using (Mega -6) 
software.  
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Results and discussion 
Subjects data: 
The characteristics of the patients are summarized in Table (1). The results indicated a significant correlation 
between the occurrence of bladder cancer with patient’s ages, gender and smoking. 
Table 1: Bladder cancer and healthy profiles. 
Characteristics Healthy control Patients 
Age(years) 
Mean 
Range 
 
58 
30-50 
 
62 
30-86 
Male 
Female 
23 
2 
46 
4 
Smoking 
Yes 
no 
 
13 
12 
 
39 
11 
Family history 0 0 
 
Bladder cancer is rare in people younger than 50 years of age, even though it can occur at any age (Parag et al., 
2009; Dodurga, et al., 2011). The incidence of cancer increases directly with age with the median age at 
diagnosis of around (70) years for each gender (Lynch and Cohen, 1995). It has been observed that genetic 
alterations that are frequently seen in older adults are extremely rare in young patients. Urothelial neoplasms in 
children and young adults appear to be biologically distinct and lack genetic instability in most cases (Wild  et 
al., 2007). 
REFLP analysis of FGFR3 exon 7  
PCR analysis of FGFR3 exon 7 is shown in Figure 1. 
 
 
Figure (1): Gel electrophoresis of FGFR3 exon 7 PCR products for healthy and patients with bladder 
cancer on 3% agarose stained with Ethidium Bromide and visulized under U.V light using blood extracted 
DNA. M, ladder, 1-7 patients bladder cancer samples, 8-10 healthy control samples. 
 
The analysis of mutation using restriction fragment length polymorphism (RFLP) was performed on PCR 
products of FGFR3 exon 7 using Hae II and TseI enzymes. If there were no mutations, a 120 bp exon 7 PCR 
product will be digested by HaeII enzyme to 64- and 56-bp fragments and digested to 94 and 26 bp fragments by 
TseI enzyme, as follow and as in figures 2 and 3: 
 
FGFR3 exon 7 region/ HaeII enzyme site 
13465CGGCAGTGGCGGTGGTGGTGAGGGAGGGGGTGGCCCCTGAGCGTCATCTGCCCCCACA
GAGCGC∇TCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTG
CT 13584. 
 
FGFR3 exon 7 region/ TseI enzyme site 
1365CGGCAGTGGCGGTGGTGGTGAGGGAGGGGGTGGCCCCTGAGCGTCATCTGCCCCCACAGAG
CGCTCCCCGCACCGGCCCATCCTGCAGGCGGGG∇CTGCCGG CAACCAGACGGCGGTGCT 13584. 
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Figure (2): Gel electrophoresis of PCR products (FGFR3 exon 7) for healthy digested with Hae II enzyme 
on 3% agarose. M, ladder; 1, 3, 4, 5, 6: DNA from healthy control, lane 2: PCR undigested product. 
  
 
 
Figure (3): Gel electrophoresis of PCR products (FGFR3 exon 7) for healthy digested with TseI enzyme on 
3% agarose. M, ladder; 1, 2, 3: DNA from healthy control. 
 
These results showed that the PCR amplified regions of the FGFR3 exon 7 has only one restriction site for each 
enzymes. The REFLP molecular analysis of FGFR3 exon 7 of patient samples for both enzymes revealed one 
mutation in one patient include FGFR3 Arginine 248 Cysteine  mutation. 
Detection of FGFR3 exon 7 mutations by DNA sequencing   
The bladder cancer patients PCR products of the exon 7 and of the FGFR3 gene were screened for mutations by 
sequencing. The patients sequencing results were compared with human reference FGFR3 gene sequence 
(http:NCBI Reference Sequence).  
Among 50 patients included in this study, 47 (94%) patients were with FRGF mutations. The total number of 
detected mutations were 51 (63%) mutations. The mutations detected in exon 7 include three types, g.13515 del 
C , g.13510 del A and g.13529 ins A. The more frequent mutation was g.13515 del C which detected in 34 
patients followed by g.13510 del A and g.13529 ins A mutations which detected in 12 and 1 patients respectively. 
The A insertion mutation (13529) included in the Hae II restriction site which explain the single mutation 
detected in patients (Table (2)( Figures 4, 5, and 6). All mutations in the tables are considered novel and not 
registered in the NCBI. 
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Table (2): Mutation analysis of the exon 7 
Exone 7 
Mutation No. of mutation in 47 patients / % Change code Effect 
g.13515 del C 
GCC>G-C 
34 / 72 % Cys/Cys Framshift 
g.13510 del A 
TCA>TC- 
12 / 30% Ser/Ser 
 
Framshift 
g.13529  Ins A 
TCC>ATC 
1 / 2% Ser/Ile Framshift 
 
 
Figure (4): Site 13515 del C, nucleotide sequence (forward) in exon 7. 
 
 
 
Figure (5): Site 13510 del A, nucleotide sequence (forward) in exon 7. 
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Figure (6): Site 13529 Ins A, nucleotide sequence (forward) in exon 7. 
In this study, The REFLP molecular analysis of FGFR3 exon 7 of patient samples for both enzymes 
revealed one mutation in one patient include FGFR3 Arginine 248 Cysteine  mutation and on mutation at Serine 
249 Cysteine. 
 Mutations of the codons 248,249 and 372 of the FGFR 3 exon 7 were also detected in bladder cancer 
patients by several researchers (Cappellen et al., 1999; Passos et al., 1999; Ashraf and Herve, 2003). Other exon 
7 mutations were also reported (Johanna et al., 2005; Hernandez et al., 2006 ; Junker et al.,2008). FGFR3 gene 
mutations in bladder cancer patients were also detected by Dodurga et al.(2011) who detect mutations in the 
exon7 of the gene FGFR 3 in 12% of bladder cancer patients include Arginine 248 Cysteine and in 50% of the 
bladder cancer patients include Serine 249 Cysteine. FGFR 3 exons 7 mutations were also detected in bladder 
cancer patients by Takahiro et al. (2001) who detect 13 mutations include Arginine 248 Cysteine and Serine 249 
Cysteine of the exon 7.  
The association between bladder cancer grad and FGFR3 mutations 
Our results showed that there is a good correlation between the development of bladder cancer and FGFR3 
mutations (Table 4). The results showed that the exon 7,  g.1315 delC mutation is a correlated with the initiation 
of tumor since it detected in all grads and consist of the majority of detected mutations (36/81, 44.4%). On the 
other hand, exons 7 mutations, g.13529 ins A, g.13510 del A, showed to have importance in cancer initiation and 
development since they are detected in the early grade (G1) and in 38(80.9%) patients of 47. 
Table (3): The number of mutations of the FGFR3 Exon 7 in different cancer grads. 
        Mutation 
Grade 
g.13515 del C g.13515 del C   g.13529 ins A Total 
G1 12 8 3 23 
G2 12 2 - 14 
G3 12 2 - 14 
Total 36 12 3 51 
Previous studies indicated a strong correlation between FGFR3 mutations and the stage/grade of the 
tumor (van Rhijn  et al 2001; Hernandez  et al., 2006). No significant correlation between FGFR3 expression 
and stage or grade of the tumor (Matsumoto  et al., 2004). 
In a study by (Khaldon  et al., 2010) find a significant correlation (p < 0.001) between the stage of the 
tumor and FGFR3 mutations. However, in contrast to other studies, they could not find any correlation between 
the grade of the tumor and FGFR3 mutations. FGFR3 protein expression of moderate or high levels of protein in 
49% of tumors but found no relationship to tumor grade or stage. Two other studies found a relationship between 
higher expression and lower tumor grade and stage (Gomez et al., 2005).  Some of the studies have reported that 
low-stage and low-grade bladder tumors are associated with FGFR3 mutations (Van Tilborg et al., 2002; Hirao 
et al., 2005). The high frequency of FGFR3 mutations in pTa tumors, and their low frequency in pT1 and pT2–4 
tumors are consistent with the model of bladder tumor (Lee and Droller, 2000; Knowles, 1999). FGFR3 
mutations were detected at (21% pT1), (16% pT2 to pT4), twenty-seven from thirty-two (84% G1), Sixteen from 
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twenty-nine (55% G2) and five from twenty-one (7% G3) (Claude et al., 2001). FGFR3 protein expression of 
moderate or high levels of protein in 49% of tumors but found no relationship to tumor grade or stage. Other 
studies found a relationship between higher expression and lower tumor grade and stage (Gomez, et al., 2005). 
Other studies revealed that no mutations of the FGFR3 gene in bladder tumor were reported (Tomlinson et al., 
2007; Arshad et al., 2010). 
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